The Cancer Genome Atlas (TCGA), a massive U.S. effort to genetically profile 10,000 tumors, has officially come to an end. The National Cancer Institute (NCI) has announced that it will continue to intensively sequence tumors in three cancers, ovarian, colorectal and lung adenocarcinoma, with an expanded scope that incorporates detailed clinical information about the patient’s health, treatment history and response to therapies using data from past clinical trials.
Click here to read the full article in Nature.
